Setmelanotide vs Mazdutide
Head-to-head comparison of Setmelanotide (Setmelanotide Acetate) and Mazdutide (IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Setmelanotide | Mazdutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Setmelanotide Acetate | IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist |
| Molecular Weight | N/A | ~5,000 Da |
| Half-Life | Approximately 11-16 hours | 5-7 days |
| Amino Acids | N/A | 37 |
| Typical Dose | 1-3 mg daily | 1-6 mg weekly in obesity trials |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 80 | 28 |
| Research Status | Clinical | Clinical |
Setmelanotide Benefits
- ✓reduced hyperphagia
- ✓body-weight reduction
- ✓MC4R pathway activation
- ✓improved satiety signaling
Mazdutide Benefits
- ✓clinically meaningful weight loss
- ✓better glycemic control
- ✓reduced waist circumference
- ✓improved lipid profile
Setmelanotide Dosing
1 mg SC daily|titrate weekly to 2-3 mg/day|follow study or label-based escalation
Mazdutide Dosing
Once-weekly SC titration|Dose escalation every 4 weeks|Use with lifestyle modification
Setmelanotide Side Effects
- ⚠hyperpigmentation
- ⚠nausea
- ⚠injection-site reactions
- ⚠fatigue
Mazdutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠constipation
Research Overview
Setmelanotide
Setmelanotide has shown clinically meaningful reductions in hunger and weight in POMC, PCSK1, and LEPR-related obesity. It is one of the most important mechanistic peptides for rare-disease obesity research.
Mazdutide
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.